Virtu Financial LLC Buys New Holdings in Monopar Therapeutics Inc. $MNPR

Virtu Financial LLC purchased a new position in Monopar Therapeutics Inc. (NASDAQ:MNPR) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 10,009 shares of the company’s stock, valued at approximately $654,000.

A number of other institutional investors also recently bought and sold shares of the business. Invesco Ltd. acquired a new stake in shares of Monopar Therapeutics in the fourth quarter worth $219,000. ADAR1 Capital Management LLC lifted its position in Monopar Therapeutics by 79.9% during the fourth quarter. ADAR1 Capital Management LLC now owns 233,908 shares of the company’s stock valued at $15,274,000 after purchasing an additional 103,909 shares during the period. Virtus Investment Advisers LLC acquired a new position in Monopar Therapeutics during the fourth quarter valued at $233,000. Millennium Management LLC boosted its holdings in Monopar Therapeutics by 945.5% in the fourth quarter. Millennium Management LLC now owns 76,674 shares of the company’s stock valued at $5,007,000 after purchasing an additional 69,340 shares during the last quarter. Finally, Janus Henderson Group PLC grew its position in Monopar Therapeutics by 2.3% during the 4th quarter. Janus Henderson Group PLC now owns 1,317,410 shares of the company’s stock worth $85,908,000 after purchasing an additional 30,042 shares during the period. 1.83% of the stock is owned by hedge funds and other institutional investors.

Monopar Therapeutics Stock Up 1.8%

MNPR stock opened at $68.66 on Tuesday. Monopar Therapeutics Inc. has a 52-week low of $29.18 and a 52-week high of $105.00. The firm has a market cap of $460.02 million, a P/E ratio of -36.14 and a beta of 1.52. The company’s 50-day simple moving average is $59.89 and its 200-day simple moving average is $61.79.

Monopar Therapeutics (NASDAQ:MNPR) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.46) earnings per share for the quarter, beating the consensus estimate of ($0.87) by $0.41. On average, analysts anticipate that Monopar Therapeutics Inc. will post -2.82 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Monopar Therapeutics in a research note on Tuesday, April 21st. Chardan Capital reaffirmed a “buy” rating and set a $100.00 target price on shares of Monopar Therapeutics in a report on Monday, March 30th. HC Wainwright reiterated a “buy” rating on shares of Monopar Therapeutics in a research report on Tuesday, June 2nd. Piper Sandler set a $105.00 price target on Monopar Therapeutics in a report on Tuesday, June 2nd. Finally, Wall Street Zen cut shares of Monopar Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, June 14th. Two research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $107.91.

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.